Ko-Chung Lin, PharmaEssentia CEO
April 21, 2023 10:58 AM EDT
Financing
R&D

Phar­maEssen­tia se­cures $462M+ to fur­ther growth of Besre­mi and its pipeline

Tyler Patchen

News Reporter

Phar­maEssen­tia an­nounced an of­fer­ing of 34 mil­lion shares of its com­mon stock, pulling in $462.7 mil­lion in the process.

On Fri­day, the Tai­wanese phar­ma com­pa­ny …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

A service from the Financial Times